Related Experiment Video

Updated: Jun 12, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.6K

SETD5-Coordinated LC3B Methylation Inhibits Autophagy in Ovarian Cancer

Yanan Hou1, Mingyang Li1, Ziwei Zhang1

  • 1Department of Basic Medicine, School of Medicine, Jiangsu University, Zhenjiang, China.

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology
|June 11, 2025
PubMed

Insights

This study reveals that SETD5 methylates nuclear LC3B, impacting autophagy and ovarian cancer cell migration. This novel methylation mechanism offers potential therapeutic targets for ovarian cancer.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • Microtubule-associated protein 1A/1B-light chain 3 (MAP1LC3/LC3) is crucial for autophagy.
  • Post-translational modifications (PTMs) regulate LC3 function, but methylation's role is unclear.

Purpose of the Study:

  • To investigate the effect of protein methylation on LC3B function.
  • To elucidate the role of SETD5-mediated LC3B methylation in ovarian cancer.

Main Methods:

  • Co-immunoprecipitation to identify SETD5 interaction with LC3B.
  • Mass spectrometry to identify methylation sites on LC3B (lysines 5 and 65).
  • Analysis of gene expression and autophagy markers in ovarian cancer cells.

Main Results:

  • SETD5 methylates nuclear LC3B at K5 and K65, promoting its nuclear retention.
  • Methylated LC3B suppresses the transcription of autophagy-related genes (ATGs) by binding PRDM10.
  • LC3B methylation inhibits autophagy and enhances ovarian cancer cell migration.

Conclusions:

  • A novel SETD5-mediated methylation of LC3B is identified.
  • This mechanism regulates nuclear LC3B function in autophagy and ovarian cancer cell migration.
  • The findings suggest potential therapeutic targets for ovarian cancer.
Keywords:
LC3BSET domain containing 5autophagyovarian cancerposttranslational modification

More Related Videos

Evaluation of LC3-II Release via Extracellular Vesicles in Relation to the Accumulation of Intracellular LC3-positive Vesicles06:58

Evaluation of LC3-II Release via Extracellular Vesicles in Relation to the Accumulation of Intracellular LC3-positive Vesicles

Published on: October 18, 2024

596
Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells09:51

Author Spotlight: A Selective Luciferase-Based Assay for Monitoring ATG4B 27 Activity in Cells

Published on: June 30, 2023

765

Related Concept Videos

Autophagy01:27

Autophagy

Autophagy is a self-digesting process by which a cell protects itself from threats both within and outside the cell, ranging from abnormal proteins to invading bacteria. In this process, obsolete components of the cell and invading microbes are degraded by hydrolytic enzymes active in an acidic environment of the lysosomal lumen.
An autophagic pathway consists of a series of signaling events activated in response to diverse stress and physiological conditions such as food deprivation,...
4.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
2.6K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K